Compare MUX & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUX | SLBT |
|---|---|---|
| Founded | 1979 | N/A |
| Country | Canada | Taiwan |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 644.9M |
| IPO Year | 1994 | 2025 |
| Metric | MUX | SLBT |
|---|---|---|
| Price | $9.17 | $0.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.40 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 46.5K |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $197,553,000.00 | N/A |
| Revenue This Year | $19.23 | N/A |
| Revenue Next Year | $34.88 | N/A |
| P/E Ratio | $96.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $0.57 |
| 52 Week High | $29.70 | $6.25 |
| Indicator | MUX | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 22.06 | 22.09 |
| Support Level | N/A | N/A |
| Resistance Level | $20.62 | $1.75 |
| Average True Range (ATR) | 0.82 | 0.13 |
| MACD | -0.40 | -0.01 |
| Stochastic Oscillator | 0.34 | 4.94 |
McEwen Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. Its Other operations include: Fox Complex, Gold Bar Complex, Project Fenix, and Los Azules. The company generates its revenue from gold and silver production. Its operating segments include Canada, United States, Mexico, MSC and McEwen Copper, of which it derives maximum revenue from USA.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.